サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790381

腫瘍ベースの分子診断市場規模、シェア、動向分析レポート：タイプ別、製品別、技術別、地域別、セグメント別予測、2025年～2033年

Oncology Based Molecular Diagnostics Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Lung Cancer), By Product (Instruments, Reagents), By Technology (PCR, Sequencing), By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 136 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
腫瘍ベースの分子診断市場規模、シェア、動向分析レポート：タイプ別、製品別、技術別、地域別、セグメント別予測、2025年～2033年
出版日: 2025年07月25日
発行: Grand View Research
ページ情報: 英文 136 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

腫瘍ベース分子診断市場概要

腫瘍ベース分子診断の世界市場規模は、2024年に37億5,000万米ドルと推定され、2025～2033年にかけてCAGR 5.5%で成長し、2030年には63億5,000万米ドルに達すると予測されています。この市場は、分子技術を通じて遺伝子変異、遺伝子発現パターン、腫瘍特異的バイオマーカーを同定することにより、さまざまながんの検出、予後予測、モニタリングをサポートします。

成長の原動力は、世界のがん罹患率の増加、精密医療の採用拡大、PCR、NGS、リキッドバイオプシープラットフォームなどの診断技術における継続的な技術革新です。

さらに、がんの早期発見と個別化治療戦略に対する需要の高まりが、ヘルスケアシステム全体における市場拡大に寄与しています。

腫瘍ベースの分子診断では、DNA、RNA、またはタンパク質を分析して、がんに関連する遺伝子の変化を検出し、臨床的判断を導きます。これらの検査は、様々ながんに関連する特定の変異、遺伝子発現、バイオマーカーの同定を助け、より正確な診断、予後、治療選択を可能にします。これらの検査は、乳がん、肺がん、大腸がん、前立腺がんの検出に一般的に用いられています。

これらの診断法は、患者を標的療法に適合させ、治療効果をモニタリングすることにより、個別化医療において重要な役割を果たします。その用途は、病院の検査室、標準検査室、研究機関など多岐にわたります。PCR、次世代シーケンス（NGS）、リキッドバイオプシーなどの技術の継続的な向上により、これらの検査はより効率的で利用しやすくなっています。がん治療が個別化治療へとシフトする中、分子診断学はがん管理の重要な要素となっています。

目次

第1章 腫瘍ベースの分子診断市場：調査手法と範囲

第2章 腫瘍ベースの分子診断市場：エグゼクティブサマリー

  • 市場スナップショット
  • タイプと製品スナップショット
  • 技術スナップショット
  • 競合情勢のスナップショット

第3章 腫瘍ベースの分子診断市場の変数、動向、範囲

  • 市場セグメンテーションと範囲
  • 市場系統の展望
    • 親市場展望
    • 関連/補助市場展望
  • 市場力学
  • 市場促進要因分析
    • 世界のがん罹患率の上昇
    • 精密医療の導入
    • 分子検査技術の進歩
  • 市場抑制要因分析
    • 検査と設備の高コスト
    • 一貫性のない償還と規制の枠組み
    • 資源の乏しい地域でのアクセス制限
  • ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析

第4章 腫瘍ベースの分子診断市場：タイプ別、推定・動向分析

  • 腫瘍ベースの分子診断市場：タイプ変動分析
  • 乳がん
  • 前立腺がん
  • 大腸がん
  • 子宮頸がん
  • 肝臓がん
  • 肺がん
  • 血液がん
  • 腎臓がん
  • その他

第5章 腫瘍ベースの分子診断市場：製品別、推定・動向分析

  • 腫瘍ベースの分子診断市場：製品変動分析
  • 機器
  • 試薬
  • その他

第6章 腫瘍ベースの分子診断市場：技術別、推定・動向分析

  • 腫瘍ベースの分子診断市場：技術変動分析
  • PCR
  • in situ-ハイブリダイゼーション
  • イナート
  • チップとマイクロアレイ
  • 質量分析
  • シーケンス
  • TMA
  • その他

第7章 腫瘍ベースの分子診断市場：地域ビジネス分析

  • 地域市場のスナップショット
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 企業分類
  • 戦略マッピング
    • 新型の発売
    • パートナーシップ
    • 取得
    • コラボレーション
    • 資金調達
  • 主要企業の市場シェア分析（2024年）
  • 企業ヒートマップ分析
  • 企業プロファイル
    • Abbott
    • Bayer AG
    • BD
    • Cepheid
    • Agilent Technologies, Inc.
    • Danaher
    • Hologic, Inc.
    • Qiagen
    • F. Hoffmann-La Roche Ltd.
    • Siemens
    • Sysmex
図表

List of Tables

  • Table. 1. List Of Secondary Sources
  • Table. 2. List Of Abbreviation
  • Table. 3. Global Oncology Based Molecular Diagnostics Market, By Region, 2021 - 2030 (USD Million)
  • Table. 4. Global Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 5. Global Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 6. Global Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 7. North America Oncology Based Molecular Diagnostics Market, By Country, 2021 - 2030 (USD Million)
  • Table. 8. North America Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 9. North America Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 10. North America Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 11. U.S. Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 12. U.S. Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 13. U.S. Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 14. Canada Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 15. Canada Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 16. Canada Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 17. Mexico Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 18. Mexico Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 19. Mexico Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 20. Europe Oncology Based Molecular Diagnostics Market, By Country, 2021 - 2030 (USD Million)
  • Table. 21. Europe Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 22. Europe Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 23. Europe Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 24. UK Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 25. UK Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 26. UK Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 27. Germany Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 28. Germany Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 29. Germany Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 30. France Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 31. France Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 32. France Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 33. Italy Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 34. Italy Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 35. Italy Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 36. Spain Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 37. Spain Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 38. Spain Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 39. Sweden Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 40. Sweden Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 41. Sweden Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 42. Norway Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 43. Norway Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 44. Norway Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 45. Denmark Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 46. Denmark Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 47. Denmark Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 48. Asia Pacific Oncology Based Molecular Diagnostics Market, By Country, 2021 - 2030 (USD Million)
  • Table. 49. Asia Pacific Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 50. Asia Pacific Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 51. Asia Pacific Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 52. Japan Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 53. Japan Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 54. Japan Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 55. China Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 56. China Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 57. China Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 58. India Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 59. India Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 60. India Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 61. Australia Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 62. Australia Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 63. Australia Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 64. Thailand Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 65. Thailand Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 66. Thailand Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 67. South Korea Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 68. South Korea Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 69. South Korea Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 70. Latin America Oncology Based Molecular Diagnostics Market, By Country, 2021 - 2030 (USD Million)
  • Table. 71. Latin America Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 72. Latin America Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 73. Latin America Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 74. Brazil Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 75. Brazil Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 76. Brazil Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 77. Argentina Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 78. Argentina Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 79. Argentina Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 80. MEA Oncology Based Molecular Diagnostics Market, By Country, 2021 - 2030 (USD Million)
  • Table. 81. MEA Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 82. MEA Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 83. MEA Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 84. South Africa Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 85. South Africa Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 86. South Africa Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 87. Saudi Arabia Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 88. Saudi Arabia Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 89. Saudi Arabia Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 90. UAE Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 91. UAE Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 92. UAE Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 93. Kuwait Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD)
  • Table. 94. Kuwait Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 95. Kuwait Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Market Summary
  • Fig. 4 Market Segmentation & Scope
  • Fig. 5 Market Size and Growth Prospects
  • Fig. 6 Global Oncology Based Molecular Diagnostics Market- Key Market Driver Analysis
  • Fig. 7 Global Oncology Based Molecular Diagnostics Market - Key Market Restraint Analysis
  • Fig. 8 Penetration & Growth Prospect Mapping
  • Fig. 9 Global Oncology Based Molecular Diagnostics Market - Porter's Analysis
  • Fig. 10 Global Oncology Based Molecular Diagnostics Market - PESTEL Analysis
  • Fig. 11 Global Oncology Based Molecular Diagnostics Market Type Outlook Key Takeaways
  • Fig. 12 Global Oncology Based Molecular Diagnostics Market: Type Movement Analysis
  • Fig. 13 Breast Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Prostate Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Colorectal Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Cervical Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Liver Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Lung Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Blood Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Kidney Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Others Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Global Oncology Based Molecular Diagnostics Market Product Outlook Key Takeaways
  • Fig. 23 Global Oncology Based Molecular Diagnostics Market: Product Movement Analysis
  • Fig. 24 Instruments Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Reagents Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Others Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Global Oncology Based Molecular Diagnostics Market Technology Outlook Key Takeaways
  • Fig. 28 Global Oncology Based Molecular Diagnostics Market: Technology Movement Analysis
  • Fig. 29 PCR Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 30 In Situ Hybridization Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 31 INAAT Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Chips and Microarrays Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 33 Mass Spectrometry Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Sequencing Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 35 TMA Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Others Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Regional Marketplace: Key Takeaways
  • Fig. 38 Global Oncology Based Molecular Diagnostics Market: Regional Movement Analysis
  • Fig. 39 North America Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 40 US Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 41 Canada Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 42 Mexico Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 43 Europe Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 44 UK Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 45 Germany Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 46 France Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 48 Italy Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 49 Denmark Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 51 Norway Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 53 Japan Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 54 China Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 55 India Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 56 South Korea Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 58 Thailand Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 59 Latin America Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 60 Brazil Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 61 Argentina Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 62 MEA Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 63 South Africa Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 64 Saudi Arabia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 65 UAE Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 66 Kuwait Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 67 Strategy Framework
目次
Product Code: 978-1-68038-699-8

Oncology Based Molecular Diagnostics Market Summary

The global oncology based molecular diagnostics market size was estimated at USD 3.75 billion in 2024 and is projected to reach USD 6.35 billion by 2030, growing at a CAGR of 5.5% from 2025 to 2033. This market supports the detection, prognosis, and monitoring of various cancers by identifying genetic mutations, gene expression patterns, and tumor-specific biomarkers through molecular techniques.

Growth is driven by the increasing global cancer burden, growing adoption of precision medicine, and continued innovation in diagnostic technologies such as PCR, NGS, and liquid biopsy platforms.

In addition, rising demand for early cancer detection and personalized therapeutic strategies contributes to market expansion across healthcare systems.

Oncology-based molecular diagnostics involve analyzing DNA, RNA, or proteins to detect cancer-related genetic alterations and guide clinical decisions. These tests help identify specific mutations, gene expressions, or biomarkers associated with various cancers, allowing for more accurate diagnosis, prognosis, and treatment selection. They are commonly used to detect breast, lung, colorectal, and prostate cancers.

These diagnostics play a key role in personalized medicine by helping match patients with targeted therapies and monitoring treatment response. Applications span across hospital labs, reference labs, and research institutions. With continuous improvements in technologies like PCR, next-generation sequencing (NGS), and liquid biopsy, these tests are becoming more efficient and accessible. With oncology care shifting toward individualized treatment, molecular diagnostics have become a critical component of cancer management.

Global Oncology Based Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oncology based molecular diagnostics market report based on product, technology, type, and region:

  • Type Outlook (Revenue, USD Million; 2021 - 2033)
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Blood Cancer
  • Kidney Cancer
  • Others
  • Product Outlook (Revenue, USD Million; 2021 - 2033)
  • Instruments
  • Reagents
  • Others
  • Technology Outlook (Revenue, USD Million; 2021 - 2033)
  • PCR
  • In situ hybridization
  • INAAT
  • Chips and microarrays
  • Mass spectrometry
  • Sequencing
  • TMA
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

ac

Table of Contents

Chapter 1. Oncology Based Molecular Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Product Segment
      • 1.1.1.3. Technology segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Oncology Based Molecular Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Product Snapshot
  • 2.3. Technology Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Oncology Based Molecular Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising Global Cancer Prevalence
    • 3.4.2. Adoption of Precision Medicine
    • 3.4.3. Advances in Molecular Testing Technologies
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Costs of Testing and Equipment
    • 3.5.2. Inconsistent Reimbursement and Regulatory Frameworks
    • 3.5.3. Limited Access in Low-Resource Regions
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Oncology Based Molecular Diagnostics Market: Type Movement Analysis
  • 4.2. Breast Cancer
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Prostate Cancer
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Colorectal Cancer
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Cervical Cancer
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Liver Cancer
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Lung Cancer
    • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Blood Cancer
    • 4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.9. Kidney Cancer
    • 4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.10. Others
    • 4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis

  • 5.1. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
  • 5.2. Instruments
    • 5.2.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.3. Reagents
    • 5.3.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4. Others
    • 5.4.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis

  • 6.1. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
  • 6.2. PCR
    • 6.2.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3. In situ hybridization
    • 6.3.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4. INAAT
    • 6.4.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Chips and microarrays
    • 6.5.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Mass spectrometry
    • 6.6.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Sequencing
    • 6.7.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.8. TMA
    • 6.8.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oncology Based Molecular Diagnostics Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Oncology Based Molecular Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Type Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Abbott
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Bayer AG
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. BD
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Cepheid
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Agilent Technologies, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Danaher
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Hologic, Inc.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Qiagen
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Type Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. F. Hoffmann-La Roche Ltd.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Type Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Siemens
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Type Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Sysmex
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Type Benchmarking
      • 8.5.11.4. Strategic Initiatives